Long-term follow-up for patients treated with zamtocabtagene autoleucel

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study monitors patients who have previously received zamtocabtagene autoleucel, a type of CAR T-cell therapy, for non-Hodgkin lymphoma. Participants will be followed for up to 15 years to assess any long-term adverse events related to the gene therapy, as well as the persistence of CAR T-cells and overall efficacy. The study aims to gather data on delayed adverse events and the safety profile of the treatment over an extended period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Received zamtocabtagene autoleucel in a North American Miltenyi Biomedicine-sponsored clinical study and have not withdrawn consent to be followed or been deemed lost to follow-up.
* Provided written informed consent to participate in this study.

Exclusion Criteria:

* None

Where it's running

• Banner MD Anderson Cancer Center
  Gilbert, Arizona, United States Recruiting
• Stanford University
  Stanford, California, United States Recruiting
• Yale University
  New Haven, Connecticut, United States Recruiting
• Robert H Lurie Cancer Center
  Chicago, Illinois, United States Recruiting
• University of Kansas Cancer Center
  Westwood, Kansas, United States Recruiting
• Dana Farber Cancer Institute
  Boston, Massachusetts, United States Recruiting

Study contacts

• Study coordinator: Sadie Swift
• Email: clinicaltrials@miltenyi.com
• Phone: 617-218-0044

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CAR-T cell therapy for relapsed or refractory DLBCL

  This study is testing a new CAR-T cell therapy to see if it can help people with tough-to-treat diffuse large B cell lymphoma feel better after other treatments haven’t worked.

  Recruiting at 30 sites Phase 2 Miltenyi Biomedicine GmbH · Birmingham, Alabama and 31 other locations · NCT04792489

• Non-Hodgkin Lymphoma Sample Collection for MRD Testing

  This study tests a blood-based and tissue-based approach to see if a molecular residual disease test can detect lingering cancer in adults with aggressive NHL who are starting standard therapy.

  Recruiting Natera, Inc. · Austin, Texas · NCT07750886

• Rituximab and Tafasitamab with Allogeneic NK Cells for relapsed or refractory B-cell NHL

  This trial tests whether giving allogeneic NK cells with Rituximab, Tafasitamab, and IL-2 can help people with relapsed or refractory B-cell non-Hodgkin lymphoma who have tried at least two prior therapies.

  Recruiting Phase 1 Case Comprehensive Cancer Center · Cleveland, Ohio and 1 other locations · NCT07225439

• Gene therapy for certain blood cancers

  This study is testing a new gene therapy called VNX-101 to see if it can help people with certain types of blood cancers that haven't responded to other treatments.

  Recruiting at 11 sites Phase 1/2 Vironexis Biotherapeutics Inc. · Duarte, California and 10 other locations · NCT06533579

• Epcoritamab treatment for certain types of lymphoma

  This study is testing if adding a new treatment called epcoritamab to CAR T cell therapy can help people with certain types of lymphoma who haven't fully responded to previous treatments.

  Recruiting Phase 2 Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania · NCT06458439

• T-Cell Therapy for Adults with Relapsed B-Cell Non-Hodgkin's Lymphoma

  This study is testing a new T-cell therapy to see if it can help adults with relapsed B-cell non-Hodgkin's lymphoma feel better.

  Recruiting at 5 sites Phase 1/2 Estrella Immunopharma, Inc. · Sacramento, California and 4 other locations · NCT06343311

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.